Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).

Search TravelDoctorOnline

Authors: Hatano K,Goldberg JB,Pier GB,
Address: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Journal: Infect Immun.


Publication: 1995 Jan;63(1):21-6.

abstract

Virulent strains of Pseudomonas aeruginosa are either of a nonmucoid, lipopolysaccharide (LPS)-smooth or mucoid, LPS-rough phenotype, and immunity to these different variants is efficiently mediated by antibodies specific to O antigens or mucoid exopolysaccharide (also called alginate), respectively. In addition to O side chains and core polysaccharide components, the LPS of P. aeruginosa also contains neutral-polysaccharide components that express antigenic determinants common to many clinical isolates. We evaluated antibodies specific to neutral polysaccharides for the ability to mediate opsonic killing and protective immunity. Antibodies to these antigens mediated opsonic killing of poorly virulent nonmucoid LPS-rough isolates but not of isogenic strains with either a LPS-smooth or a mucoid phenotype. Antibodies to neutral-polysaccharide antigens also failed to protect neutropenic mice from challenge with modest doses of LPS-smooth P. aeruginosa strains (< 10(3) CFU per mouse), whereas O-antigen-specific antibodies were highly protective. Antibodies to neutral polysaccharides deposited significantly (P = 0.002) more C3 onto LPS-rough strains than did antibodies to O side chains, but this situation was reversed when isogenic LPS-smooth strains were tested. Given that protective immunity against P. aeruginosa must be directed against either nonmucoid LPS-smooth strains or mucoid LPS-rough strains, it appears that antibodies specific to neutral-polysaccharide antigens do not protect against P. aeruginosa infection. Lack of protection is likely due to the ability of both O side chains and mucoid exopolysaccharide (alginate) to interfere with the opsonic killing activity of neutral-polysaccharide-specific antibodies.



Related Articles
Review Pseudomonas aeruginosa antigens as potential vaccines.
FEMS Microbiol Rev. 1997
Review Pseudomonas aeruginosa antigens as potential vaccines.
Stanislavsky ES, Lam JS. FEMS Microbiol Rev. 1997 Nov; 21(3):243-77.
Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.
J Immunol. 1991
Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.
Pier GB, Grout M, Desjardins D. J Immunol. 1991 Sep 15; 147(6):1869-76.
Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.
J Bacteriol. 1993
Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule.
Hatano K, Goldberg JB, Pier GB. J Bacteriol. 1993 Aug; 175(16):5117-28.
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
Infect Immun. 1994
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
Hatano K, Boisot S, DesJardins D, Wright DC, Brisker J, Pier GB. Infect Immun. 1994 Sep; 62(9):3608-16.
Review Polysaccharide antigens of Pseudomonas aeruginosa.
Crit Rev Microbiol. 1990
Review Polysaccharide antigens of Pseudomonas aeruginosa.
Knirel YA. Crit Rev Microbiol. 1990; 17(4):273-304.
Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
Infect Immun. 2011
Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB. Infect Immun. 2011 Mar; 79(3):1289-99. Epub 2010 Dec 13.
Lipopolysaccharide O-antigen chain length regulation in Pseudomonas aeruginosa serogroup O11 strain PA103.
J Bacteriol. 2008
Lipopolysaccharide O-antigen chain length regulation in Pseudomonas aeruginosa serogroup O11 strain PA103.
Kintz E, Scarff JM, DiGiandomenico A, Goldberg JB. J Bacteriol. 2008 Apr; 190(8):2709-16. Epub 2007 Dec 7.
Review Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.
Int J Med Microbiol. 2007
Review Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.
Pier GB. Int J Med Microbiol. 2007 Sep; 297(5):277-95. Epub 2007 Apr 27.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.